Ankyra in the News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Press Releases
Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research. Dr. Emens is an experienced...
Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors
Data to be presented during Society for Immunotherapy of Cancer 37th Annual Meeting BOSTON — Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that new, preclinical data highlighting the...
Ankyra Therapeutics Appoints Joseph J. Elassal, M.D., MBA, a Veteran Immuno-oncology Expert, as Chief Medical Officer
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer. Dr. Elassal will fill the role formerly...
Ankyra Therapeutics Announces Research Collaboration with the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign
BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has entered into a formal research collaboration with the College of Veterinary Medicine at the University of Illinois Urbana-Champaign. Ankyra is developing a novel anchored...
Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra...
Ankyra Therapeutics Appoints Howard L. Kaufman, M.D. as President and Chief Executive Officer
Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...